Ghana’s $109 million health deal rejection: the moment Accra chose data control over dollars
Accra has drawn a line that extends far beyond the borders of its own health system. By turning down a US health agreement worth roughly $109 million over five years, Ghana has forced a question that many African capitals have long avoided: when foreign aid comes with strings attached to patient records and pathogen samples, what is a nation’s sovereignty actually worth?
The answer from Ghana’s government was swift and unambiguous. No amount of money justifies handing over control of the country’s most sensitive health information.
The decisive break with Washington
The agreement, which would have delivered about $109 million in US funding over five years as part of a broader package valued at roughly $300 million when Ghana’s own contributions were factored in, was rejected outright. President John Dramani Mahama confirmed the decision during an appearance at the Council on Foreign Relations in New York on September 25, and his words landed with force.
“Who takes another country’s medical records?” Mahama asked, framing the choice as a matter of basic dignity rather than diplomatic calculation.
According to the Ghanaian president, the draft would have required the transfer of pathogen profiles and medical data to the United States. It also allegedly imposed counterpart funding obligations on Ghana and contained provisions affecting control over medical products entering the country. For Mahama, those terms were simply “humiliating.”
What the US side was actually seeking
The controversy deserves a closer look than the headline quote alone.
Ghana did not reject $100 million merely because it originated in Washington. The sticking point was the conditions attached to the money.
Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, indicated that certain provisions would have allowed access to sensitive health data under circumstances that could potentially identify individuals. In his assessment, the scope of that access went well beyond what is normally required.
Reporting has also suggested that the Ghanaian draft envisioned access to health data and pathogen information for 16 US companies. At the same time, several clauses in the new US health agreements remain difficult to scrutinize publicly, since not all negotiated texts have been released.
A nuance is therefore necessary: it would be excessive to claim that the United States demanded unrestricted access to “all Ghanaian medical data.” What is documented, however, is Ghana’s concern about the breadth of access to health data and pathogen information.
Why pathogen and patient data carry such weight
Behind medical records lies a question of power.
Health data reveals which diseases are circulating, where they are spreading, which populations are most exposed, and how outbreaks evolve. Pathogen data can carry enormous scientific value, feeding research into vaccines, treatments, and surveillance of emerging epidemics.
That is precisely what has fueled anxiety among several African governments.
In February 2026, Jean Kaseya, director-general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already voiced serious concerns about data- and pathogen-sharing provisions in the new US health agreements. Reports at the time indicated that some agreements required rapid sharing of sensitive data without guaranteeing African countries access to the treatments or vaccines that might result from that information.
Ghana, in other words, is not an isolated case.
Accra’s push to shed dependence on foreign aid
The rejection also lands in a specific context.
Since the suspension of a large share of US aid programs, Ghana has been working to reduce its reliance on external funding. In February 2025, the Ghanaian presidency estimated the shortfall caused by the suspension of USAID financing at $156 million, including $78.2 million directly tied to essential health programs.
The Mahama government is now promoting the idea of “health sovereignty.” That direction was reinforced in September with the launch of the report A Sovereign Future for Health, presented under the Accra Reset initiative. The document proposes reducing Global South dependence on external financing and strengthening domestic health systems.
Accra’s message is fairly clear: Ghana wants to keep working with foreign partners, but on terms it considers more balanced.
The medicines question: another point of friction
Another element Mahama raised is particularly sensitive.
According to the president, the draft would have exempted certain medicines and medical products supplied under the program from oversight by Ghana’s Food and Drugs Authority (FDA).
That claim has not been publicly confirmed in detail by the US government, which, when asked, said it does not comment on the details of bilateral negotiations.
But if the provision did match the text presented to Ghana’s government, it explains part of Accra’s firmness: for Ghanaian authorities, health financing should not come at the cost of weakening the national regulator’s ability to oversee medical products used on its own soil.
Washington’s response: limited and guarded
Washington has not publicly detailed the contested clauses.
A US State Department spokesperson said the United States does not disclose the details of bilateral negotiations, while maintaining that Washington continues to seek ways to strengthen its partnership with Ghana.
The absence of a full public release of the text leaves several essential questions unresolved.
- Exactly what data would have been accessible?
- To which US companies or institutions?
- Under what circumstances could individuals have been identified?
- How long would the data have been retained?
- What legal safeguards would have protected Ghanaian patients?
On these points, public information remains incomplete.
A debate that reaches well beyond Ghana
That may be the real issue at stake.
For decades, many African health systems have depended on funding, medicines, equipment, and programs from abroad. Those partnerships have saved lives and helped combat major diseases.
But the digital transformation of health is now changing the nature of cooperation. Aid is no longer only about money, medicines, or equipment. It can also grant access to a strategic resource: data.
Ghana has just reminded the world that it intends to keep control of that resource.
Mahama says his government rejected the draft after review by the Ministry of Health and consideration by the Cabinet. He also says the decision had the backing of the entire government and was taken very quickly.
Ghana will now have to show it can fill the funding gap left behind without compromising its health programs.
But for Accra, the choice appears to be a deliberate one: better to look for other partners than to sign an agreement the government views as incompatible with health sovereignty and the protection of Ghanaians’ data.
The question Ghana is now putting to its foreign partners is simple: when Africa receives aid to care for its people, must it also surrender control over information about those people?
The debate has probably only just begun.
